statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono)

Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono) Ono Announces Results of Tender Offer to...

Kuehn Law Encourages HIBB, CRGY, DCPH, and HCP Investors to Contact Law Firm

Kuehn Law Encourages HIBB, CRGY, DCPH, and HCP Investors to Contact Law Firm Kuehn Law Encourages HIBB, CRGY, DCPH, and HCP Investors to Contact Law Firm PR Newswire NEW YORK, June 3, 2024 NEW YORK...

Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer...

SHAREHOLDER ALERT: Halper Sadeh LLC Continues to Investigate SQSP, DPSI, DCPH, HRT

SHAREHOLDER ALERT: Halper Sadeh LLC Continues to Investigate SQSP, DPSI, DCPH, HRT SHAREHOLDER ALERT: Halper Sadeh LLC Continues to Investigate SQSP, DPSI, DCPH, HRT PR Newswire NEW YORK, May 29...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SQSP, AGS, DCPH

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SQSP, AGS, DCPH SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SQSP, AGS, DCPH PR Newswire NEW YORK, May 20, 2024 NEW YORK, May 20...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AGS, HCP, DCPH

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AGS, HCP, DCPH SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AGS, HCP, DCPH PR Newswire NEW YORK, May 13, 2024 NEW YORK, May 13...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DCPH, IONM, DPSI

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DCPH, IONM, DPSI SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DCPH, IONM, DPSI PR Newswire NEW YORK, May 10, 2024 NEW YORK, May...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MCBC, DCPH, HTLF, TBNK

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MCBC, DCPH, HTLF, TBNK SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MCBC, DCPH, HTLF, TBNK PR Newswire NEW YORK, May 2, 2024 NEW...

DECIPHERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Deciphera Pharmaceuticals, Inc. - DCPH

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Deciphera Pharmaceuticals, Inc. (NasdaqGS...

Deep Dive Into Deciphera Pharmaceuticals Stock: Analyst Perspectives (5 Ratings)

Latest Ratings for DCPH
 DateFirmActionFromTo Feb 2022BarclaysDowngradesEqual-WeightUnderweight Dec 2021HC Wainwright & Co.MaintainsBuy Nov 2021Truist SecuritiesDowngradesBuyHold
 View More...

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, the United Kingdom, and the United States.

Volume	1.6M
52-Wk High	$25.61
52-Wk Low	$9.90

DCPH Deciphera Pharmaceuticals Inc

About

Feed

News

Earnings

Fundamentals